Press Release

United States Active Pharmaceutical Ingredient Market to Grow with a CAGR of 8.76% through 2028

Growing demand for personalized medicine and advancements in active pharmaceutical ingredient (API) manufacturing is expected to drive the United States Active Pharmaceutical Ingredient Market growth in the forecast period, 2024-2028. 


According to TechSci Research report, “United States Active Pharmaceutical Ingredient Market –Industry Size, Share, Trends, Competition Forecast & Opportunities, 2018-2028F”, the United States Active Pharmaceutical Ingredient Market stood at USD 21.93 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 8.76% through 2028. The United States Active Pharmaceutical Ingredient (API) market is primarily driven by several key factors. The first is the rise in the prevalence of chronic diseases, which creates a higher demand for effective drugs and, in turn, for APIs. Advancements in pharmaceutical technologies have improved the production and efficiency of APIs, thus fueling market growth.

Additionally, the government's increasing focus on generic drugs, primarily to reduce healthcare expenses, has led to a surge in the API market. Also, increased R&D activities in the pharmaceutical sector contribute significantly to the expansion of the API market.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Active Pharmaceutical Ingredient Market


The United States Active Pharmaceutical Ingredient (API) market, a significant sector within the broader pharmaceutical industry, is responsible for the production and distribution of APIs in the United States. APIs, which are the biologically active components of pharmaceutical drugs, play a crucial role in producing the intended therapeutic effects. This market encompasses both branded and generic API production, covering all stages from initial research and development (R&D), formulation, testing, and manufacturing, to final distribution across the country.

Regulation of the US API market is primarily overseen by the Food and Drug Administration (FDA), ensuring the safety, efficacy, and quality of pharmaceutical products. The FDA imposes stringent guidelines and conducts regular inspections to enforce compliance with good manufacturing practices (GMP) and quality control standards. This regulatory oversight contributes to the overall strength and growth of the US pharmaceutical industry, promoting consumer safety and fostering innovation.

With a strong emphasis on research and development, the US API market plays a vital role in advancing medical breakthroughs and therapeutic innovations. As a crucial supply chain component, it provides the essential building blocks for formulating and producing a wide range of pharmaceutical drugs. The dynamic nature of the market, coupled with continuous advancements in technology and scientific knowledge, drives the development of new APIs, effectively supporting the ever-evolving healthcare needs of the population.

In addition to meeting domestic demand, the US API market also caters to global markets, contributing to the country's export capabilities and trade relations. The reputation of US-made APIs for their quality and compliance with international standards further enhances the competitiveness and global standing of the US pharmaceutical industry. Overall, the United States Active Pharmaceutical Ingredient (API) market serves as a critical sector within the pharmaceutical industry, responsible for the production, regulation, and distribution of APIs that form the foundation of numerous life-saving and life-enhancing medicines. Its continuous growth and innovation ensure that the US remains at the forefront of healthcare advancements, positively impacting the well-being of individuals both domestically and internationally.

The United States Active Pharmaceutical Ingredient Market is segmented into form, drug type, source, distribution channel, therapeutic application, company, regional distribution, and company.

Based on therapeutic applications, the cardiovascular disease segment is expected to continue its dominance in the United States Active Pharmaceutical Ingredient Market. This can be attributed to the high prevalence of heart disease in the country, which necessitates a strong focus on innovative cardiovascular therapeutic treatments. With a growing emphasis on research and development, pharmaceutical companies are investing in cutting-edge technologies to develop new and effective medications for cardiovascular diseases. Furthermore, the increasing adoption of precision medicine and personalized therapies in the field of cardiology is expected to contribute to the growth of the cardiovascular disease segment in the US API market. The ability to tailor treatments to individual patients based on their genetic makeup, lifestyle, and specific disease characteristics has shown promising results in improving patient outcomes and reducing the burden of cardiovascular diseases.

Moreover, the rising geriatric population in the United States is another factor driving the demand for cardiovascular therapeutic treatments. As the elderly population continues to grow, the incidence of age-related cardiovascular conditions such as hypertension, heart failure, and atherosclerosis is also increasing. This demographic trend presents significant opportunities for pharmaceutical companies to develop and market API-based medications that cater to the specific needs of the elderly population. The Cardiovascular Disease segment holds a prominent position in the US API market due to the high prevalence of heart disease, the focus on innovative treatments, and the increasing use of precision medicine. With ongoing investments in research and development, as well as the growing geriatric population, the segment is poised for continued growth and remains a key driver in the pharmaceutical industry.

Based on region, the North-East region of the United States is projected to dominate the Active Pharmaceutical Ingredient (API) market due to several key factors. This region, encompassing states such as Massachusetts, New York, and New Jersey, houses a large number of prominent pharmaceutical and biotechnology companies, thereby driving significant API production. These companies leverage the region's thriving life sciences ecosystem, which includes access to skilled talent, state-of-the-art facilities, and collaborative networks, to drive innovation in API development. Moreover, the North-East region is renowned for its robust research and development (R&D) infrastructure, including prestigious universities such as Harvard, MIT, and Columbia, as well as renowned research institutes like the Broad Institute and Rockefeller University. These institutions serve as hubs of scientific excellence, fostering cutting-edge research in pharmaceuticals and biotechnology, and contributing to advancements in API innovation.

Furthermore, supportive government policies at the federal, state, and local levels play a crucial role in nurturing the growth of the API market in the North-East region. These policies foster an environment conducive to research, development, and manufacturing activities, providing incentives for companies to invest in API production and establish a strong presence in the region. The high demand for efficient healthcare facilities in the North-East region, driven by a large population and a concentration of healthcare providers, further propels the growth of the API market. The region's hospitals, clinics, and healthcare systems require a steady supply of high-quality APIs to meet the needs of patients, driving the demand for API production and fostering the growth of the market.


Major companies operating in the United States Active Pharmaceutical Ingredient Market are:

  • Teva Pharmaceuticals USA
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Lupin Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Novartis Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Sanofi-Aventis U.S. LLC


Download Free Sample Report

Customers can also request 10% free customization on this report.


“The future of the Active Pharmaceutical Ingredient (API) industry in the United States is poised for significant growth and diversification. With increasing demand for biosimilars and advancements in recombinant technology, the industry is experiencing a transformational shift. Moreover, the rising emphasis on precision medicine and personalized therapies is opening up new avenues of opportunities for API manufacturers. The U.S. API industry is on a positive trajectory, driven by various factors such as increasing demand, technological advancements, and a focus on domestic production. By overcoming challenges and capitalizing on opportunities, the industry is well-positioned to play a crucial role in shaping the future of healthcare in the United States.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

United States Active Pharmaceutical Ingredient By Form (Tablet, Capsule, Injection, Others), By Drug Type (Innovator, Generic), By Source (In-house, Contract Manufacturing Organizations), By Distribution Channel (Online, Offline), By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal, Others), By Region, Competition, Forecast and& Opportunities, 2018-2028F”, has evaluated the future growth potential of United States Active Pharmaceutical Ingredient Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision-makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Active Pharmaceutical Ingredient Market.



Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]